In the multivariate analyses, TRIM6, as well as WHO grade, IDH status, primary therapy outcome, gender, and age, remained significantly associated with OS in Gliomas (HR = 1.591, 95% CI = 1.027–2.466, p = 0.038). This evidence concerns the gene TRIM6 and central nervous system cancer.